A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 17 Oct 2016 Number of treatment arms changed from 2 to 1. Study design was changed from randomized to non-randomized, parallel to single-group assessment.
- 05 Oct 2016 Planned number of patients changed from 100 to 60.
- 01 Oct 2014 New trial record